Editorial on the Research Topic Synthetic biology in Vertebrate Model system: New clinical and preclinical translational applications Synthetic biology represented the conceptual and technological merging of life science with engineering and information science, with the goal of enabling scientists to rationally create, design, and manipulate life with programmable functions. For more than half a century, the typical chassis cells of synthetic biology were E. coli and S. cerevisiae, and many synthetic circuits have been developed and poised to transform those cells into productive tools in the biotechnology and medicine industry (Cameron et al., 2014). However, the field of synthetic biology has expanded rapidly in the past decade (Meng and Ellis, 2020), and vertebrate cells including human cells have become novel platforms for integrating synthetic technologies, including genome editing (Shalem et al., 2014), light/chemical-sensing circuitry (Deisseroth, 2011), ligand/antigen-controlled circuitry (Morsut et al., 2016; Melenhorst et al., 2022), multiunit transgenesis (Cai et al., 2013), etc. As time goes on, the current boarder of synthetic biology field becomes vague, and synthetic technologies are present across multiple aspects of biomedical research.Here we gathered several experts in synthetic biology as the editorial group, Wang Yongming's laboratory was dedicated to the optimization of gene editing technologies, and have developed several novel tools including SlugCas9 (Hu et al., 2021) and SchCas9 (Wang et al., 2022) for potential applications in gene therapy. Zhao Yuzhen's laboratory has developed several artificial and genetically encoded fluorescent sensors, including NAD+/NADH sensors, to reveal metabolic dynamics in living model organisms (Zhao et al., 2015;Zou et al., 2020). In my laboratory, we have generated several transgenic vertebrate cancer models using synthetic sequences, which were composed of multiple regulatory units like "LeGo" blocks (Yao et al., 2018;Fei et al., 2019;Fei et al., 2021). We also employed ligand-controlled synNotch receptor and antigen-recognizing CAR receptor to engineer human T cells, which were programmed to attack human cancer cells or animal cells expressing human cancer antigens (Wang et al., 2021). In addition, we designed double-humanized animal models carrying semi-immortalized primary xenografts, and aligned the models in three-dimensional printed chips, followed by automatic drug screening and high-throughput imaging analysis, as a proof of concept combining both synthetic animal models and customer-made abiotic structures (Wu et al.,